Drug Profile
Research programme: dendritic cell vaccine - Precigen Inc/University of California
Latest Information Update: 11 Feb 2020
Price :
$50
*
At a glance
- Originator MediStem Laboratories; University of California
- Developer Medistem; University of California
- Class Cancer vaccines; Dendritic cell vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 03 Feb 2020 Intrexon Corporation is now called Precigen Inc
- 12 Mar 2014 No development reported - Preclinical for Cancer in USA (unspecified route)
- 07 Mar 2014 Medistem has been acquired by Intrexon Corporation